Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 10/20 | 0.54 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.46 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.45 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5325030 | 0.90 | PTGDR2 (0.57) | PTGDR2AKR1B1TDP1TSHRMRGPRX4 | |
| SCHEMBL14419229 | 0.88 | PTGDR2 (0.57) | PTGDR2TDP1TSHRMAPT | |
| SCHEMBL13743326 | 0.88 | MRGPRX4 (0.44) | PTGDR2MRGPRX4SLC2A1MAPT | |
| SCHEMBL14419689 | 0.87 | PTGDR2 (0.54) | PTGDR2AKR1B1TDP1TSHRMRGPRX4 | |
| SCHEMBL14419576 | 0.86 | SLC2A1 (0.45) | PTGDR2TDP1MRGPRX4SLC2A1MAPT | |
| SCHEMBL12328442 | 0.84 | POLB (0.49) | MRGPRX4MAPT | |
| SCHEMBL14355595 | 0.83 | PTGDR2 (0.50) | PTGDR2TDP1TSHRCYSLTR1MAPT | |
| SCHEMBL13715470 | 0.83 | PTGDR2 (0.55) | PTGDR2AKR1B1TDP1TSHRMAPT | |
| SCHEMBL13715350 | 0.81 | PTGDR2 (0.55) | PTGDR2TDP1TSHRMAPT | |
| SCHEMBL14419297 | 0.81 | PTGDR2 (0.57) | PTGDR2TDP1TSHRCYSLTR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1781600-B1 | BENZOIC ACID DERIVATIVES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2011-09-28 | — | — | EP | disclosed |
| US-7569723-B2 | Benzoic acid derivatives as non nucleoside reverse-transcriptase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-08-04 | — | — | US | disclosed |
| US-7569723-B2 | Benzoic acid derivatives as non nucleoside reverse-transcriptase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-08-04 | — | — | US | disclosed |
| US-20080114068-A1 | BENZOIC ACID DERIVATIVES AS NON NUCLEOSIDE REVERSE-TRANSCRIPTASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-05-15 | — | — | US | disclosed |
| US-20080114068-A1 | BENZOIC ACID DERIVATIVES AS NON NUCLEOSIDE REVERSE-TRANSCRIPTASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-05-15 | — | — | US | disclosed |
| US-7300948-B2 | Alkynyl compounds as non nucleoside reverse transcriptase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-11-27 | — | — | US | disclosed |
| US-7300948-B2 | Alkynyl compounds as non nucleoside reverse transcriptase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-11-27 | — | — | US | disclosed |
| US-7273863-B1 | Benzophenones as inhibitors of reverse transcriptase | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080114068-A1 | BENZOIC ACID DERIVATIVES AS NON NUCLEOSIDE REVERSE-TRANSCRIPTASE INHIBITORS | POLR2A, POLR1A, RTF1 | PTGDR2 2659/4885AKR1B1 410/4885TDP1 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.